The first was a proof‐of‐concept study in which patients received remission‐induction chemotherapy plus midostaurin and antifungal prophylaxis (PCZ or micafungin) for newly diagnosed AML with FLT3 mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.